JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Home・Elenco Azioni・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Chiusa

SettoreSettore sanitario

29.4 2.94

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.33

Massimo

29.56

Metriche Chiave
By Trading Economics
Entrata	-5.8M 40M
Vendite	16M 200M
P/E Media del settore	9.713 37.003
EPS	0.92
Margine di Profitto	19.839
Dipendenti	268
EBITDA	3M 59M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+56.35% upside

Dividendi
By Dow Jones
Utili prossimi	4 nov 2025

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-309M 1.7B
Apertura precedente	26.46
Chiusura precedente	29.4

Notizie sul Sentiment di mercato

By Acuity

34%

66%

94 / 373 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

29.8 / N/A Supporto e resistenza

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 nov 2025, 21:44 UTC

Utili

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3 nov 2025, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3 nov 2025, 23:34 UTC

Discorsi di Mercato

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3 nov 2025, 23:28 UTC

Utili

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3 nov 2025, 23:24 UTC

Utili

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov 2025, 23:14 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

3 nov 2025, 23:14 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3 nov 2025, 23:12 UTC

Utili

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov 2025, 23:09 UTC

Utili

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3 nov 2025, 23:09 UTC

Utili

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3 nov 2025, 23:09 UTC

Utili

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3 nov 2025, 23:06 UTC

Discorsi di Mercato

Utili

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3 nov 2025, 22:36 UTC

Discorsi di Mercato

Utili

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3 nov 2025, 22:31 UTC

Utili

Franco-Nevada 3Q EPS $1.49 >FNV

3 nov 2025, 22:31 UTC

Utili

Franco-Nevada 3Q Rev $487.7M >FNV

3 nov 2025, 22:24 UTC

Discorsi di Mercato

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3 nov 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks Agrees to Sell Stake in China Business -- WSJ

3 nov 2025, 21:59 UTC

Discorsi di Mercato

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3 nov 2025, 21:54 UTC

Discorsi di Mercato

Utili

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3 nov 2025, 21:54 UTC

Discorsi di Mercato

Utili

Global Equities Roundup: Market Talk

3 nov 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

3 nov 2025, 21:49 UTC

Utili

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3 nov 2025, 21:40 UTC

Utili

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3 nov 2025, 21:31 UTC

Discorsi di Mercato

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3 nov 2025, 21:19 UTC

Utili

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3 nov 2025, 21:11 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3 nov 2025, 21:11 UTC

Utili

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3 nov 2025, 21:07 UTC

Utili

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3 nov 2025, 21:05 UTC

Utili

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov 2025, 21:05 UTC

Utili

Palantir Technologies 3Q Net $475.6M >PLTR

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

56.35% in crescita

Previsioni per 12 mesi

Media 44.67 USD 56.35%

Alto 62 USD

Basso 31 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

29.8 / N/ASupporto e resistenza

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

94 / 373 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.